TY - JOUR
T1 - Novel MscL agonists that allow multiple antibiotics cytoplasmic access activate the channel through a common binding site
AU - Wray, Robin
AU - Wang, Junmei
AU - Iscla, Irene
AU - Blount, Paul
N1 - Funding Information:
This work was supported by Grants GM121780 (PB) and GM 079383 (JW) from the National Institutes of Health, and Grant I-1420 of the Welch Foundation.
Publisher Copyright:
© 2020 Public Library of Science. All rights reserved.
PY - 2020/1/1
Y1 - 2020/1/1
N2 - The antibiotic resistance crisis is becoming dire, yet in the past several years few potential antibiotics or adjuvants with novel modes of action have been identified. The bacterial mechanosensitive channel of large conductance, MscL, found in the majority of bacterial species, including pathogens, normally functions as an emergency release valve, sensing membrane tension upon low-osmotic stress and discharging cytoplasmic solutes before cell lysis. Opening the huge ~30Å diameter pore of MscL inappropriately is detrimental to the cell, allowing solutes from and even passage of drugs into to cytoplasm. Thus, MscL is a potential novel drug target. However, there are no known natural agonists, and small compounds that modulate MscL activity are just now being identified. Here we describe a small compound, K05, that specifically modulates MscL activity and we compare results with those obtained for the recently characterized MscL agonist 011A. While the structure of K05 only vaguely resembles 011A, many of the findings, including the binding pocket, are similar. On the other hand, both in vivo and molecular dynamic simulations indicate that the two compounds modulate MscL activity in significantly different ways.
AB - The antibiotic resistance crisis is becoming dire, yet in the past several years few potential antibiotics or adjuvants with novel modes of action have been identified. The bacterial mechanosensitive channel of large conductance, MscL, found in the majority of bacterial species, including pathogens, normally functions as an emergency release valve, sensing membrane tension upon low-osmotic stress and discharging cytoplasmic solutes before cell lysis. Opening the huge ~30Å diameter pore of MscL inappropriately is detrimental to the cell, allowing solutes from and even passage of drugs into to cytoplasm. Thus, MscL is a potential novel drug target. However, there are no known natural agonists, and small compounds that modulate MscL activity are just now being identified. Here we describe a small compound, K05, that specifically modulates MscL activity and we compare results with those obtained for the recently characterized MscL agonist 011A. While the structure of K05 only vaguely resembles 011A, many of the findings, including the binding pocket, are similar. On the other hand, both in vivo and molecular dynamic simulations indicate that the two compounds modulate MscL activity in significantly different ways.
UR - http://www.scopus.com/inward/record.url?scp=85078276384&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85078276384&partnerID=8YFLogxK
U2 - 10.1371/journal.pone.0228153
DO - 10.1371/journal.pone.0228153
M3 - Article
C2 - 31978161
AN - SCOPUS:85078276384
SN - 1932-6203
VL - 15
JO - PLoS One
JF - PLoS One
IS - 1
M1 - e0228153
ER -